APA (7th ed.) Citation

Zamarin, D., Merghoub, T., Li, Y., Hollmann, T. J., Konner, J. A., Zhou, Q., . . . Erskine, C. L. Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: A phase II trial. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Zamarin, Dmitriy, et al. Safety, Immunogenicity, and Clinical Efficacy of Durvalumab in Combination with Folate Receptor Alpha Vaccine TPIV200 in Patients with Advanced Ovarian Cancer: A Phase II Trial. BMJ Publishing Group.

MLA (9th ed.) Citation

Zamarin, Dmitriy, et al. Safety, Immunogenicity, and Clinical Efficacy of Durvalumab in Combination with Folate Receptor Alpha Vaccine TPIV200 in Patients with Advanced Ovarian Cancer: A Phase II Trial. BMJ Publishing Group.